Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 10/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | SOD1 | P00441 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676302 | 1.00 | FFAR4 (0.36) | FFAR4TACR1KCNH2SYKSOD1 | |
| SCHEMBL12676303 | 1.00 | FFAR4 (0.36) | FFAR4TACR1KCNH2SYKSOD1 | |
| SCHEMBL13454199 | 0.92 | FFAR4 (0.34) | FFAR4TACR1KCNH2SYKCNR1 | |
| SCHEMBL13454178 | 0.92 | FFAR4 (0.34) | FFAR4TACR1KCNH2SYKCNR1 | |
| SCHEMBL13454207 | 0.92 | FFAR4 (0.34) | FFAR4TACR1KCNH2SYKCNR1 | |
| SCHEMBL30724172 | 0.90 | SYK (0.34) | FFAR4SYKFLT3AURKB | |
| SCHEMBL15693710 | 0.82 | SOD1 (0.33) | FFAR4SOD1 | |
| SCHEMBL13469521 | 0.82 | SOD1 (0.33) | FFAR4SOD1 | |
| SCHEMBL12676324 | 0.80 | SLC6A2 (0.33) | FFAR4 | |
| SCHEMBL13454235 | 0.78 | MAPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593069-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2016-02-11 | — | — | US | disclosed |
| US-9162968-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2014-12-18 | — | — | US | disclosed |
| US-8722939-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2011059821-A2 | CYCLOHEXANE-1,3-DIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | FFAR4 3463/4885TACR1 2636/4885KCNH2 2136/4885 |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | FFAR4 3463/4885TACR1 2636/4885KCNH2 2136/4885 |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | FFAR4 3463/4885TACR1 2636/4885KCNH2 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.